MIRA Reports Positive Phase 1 Results for Ketamir‑2 in 57 Volunteers, No Serious AEs, Supports Once‑Daily Dosing
MIRA Pharmaceuticals, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $1.05
+2.2% in 7d after detection
Post-detection moves
1h
—
1d
+0.4%
3d
+0.5%
7d
+2.2%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS